Promise Bio Emerges from Stealth, Revolutionizing Autoimmune Disease Treatment

Promise Bio Emerges from Stealth, Revolutionizing Autoimmune Disease Treatment

Promise Bio, a Tel Aviv-based biotech company, has officially exited stealth mode, backed by pharmaceutical giants Pfizer and AstraZeneca. The company's groundbreaking AI-driven platform promises to revolutionize the diagnosis and treatment of autoimmune diseases. Beyond AI Drug Discovery Unlike many other AI-focused biotech companies, Promise Bio is not primarily focused on drug discovery. Instead, the company has developed a cloud-based platform capable of identifying specific Post-Translational Modifications (PTMs) in proteins from a single blood sample. This technology represents a significant advancement over traditional methods, which require multiple separate tests to detect these 200 different protein modifications. PTMs: Key to Precision Medicine PTMs play a crucial role in understanding and treating autoimmune diseases. By analyzing these modifications, Promise Bio can provide a more comprehensive and accurate picture of a patient's disease state. This level of precision…